(Oslo, July 10, 2026) Aker BioMarine reports continued momentum in krill oil sales in the second quarter of 2026, with revenues up 21 percent to 31.5 million USD on solid volume growth. The company also secured a new Lysoveta contract worth 4 million USD in first-year revenues and won new Superba krill oil business ranking among the company’s largest customers.
The company reports revenue of 57.9 million USD in the second quarter, an increase of 5 percent compared to the same period last year. Adjusted EBITDA came in at 12.9 million USD, 4 percent below last year.
Krill oil sales continued its strong development in the second quarter, with revenues up 21 percent year-over-year, driven by solid volume growth and higher prices as a result of product mix.
“Krill oil sales continued their strong momentum in the second quarter, with revenues up 21% year-over-year on solid volume growth. We are also pleased to have secured a new Lysoveta contract worth USD 4 million in first-year revenues, in addition to a large win for Superba Krill oil, important commercial milestones for our ingredient portfolio,” says the company’s CEO, Matts Johansen.
Krill oil growth continues
Human Health Ingredients (HHI) delivered revenue growth of 17 percent to 34.1 million USD. Sales of krill oil alone reached 31.5 million USD, an increase of 21 percent, driven mainly by solid volumes, with prices supported by product mix and a higher share of capsulated oil. Adjusted EBITDA for the segment increased 14 percent to 15.9 million USD.
Production in Houston was lower in the quarter, impacting QHP sales, but stabilized to normal levels at quarter end.
Repositioning in Consumer Health
Consumer Health Products (CHP) reported revenue of 26.4 million USD, a 6 percent decline compared with the previous year. Lang declined 4 percent on lower sales through key US retail chains, while Epion continues a marketing repositioning that is weighing on short-term revenues but is expected to be positive over time. Adjusted EBITDA came in at 1.1 million USD, reflecting lower revenues and gross profit.
Outlook and strategic direction
Human Health Ingredients expects continued year-over-year growth and improved profits, supported by good underlying demand across multiple markets. Consumer Health Products is expected to return to modest growth.
The sale process for Understory is ongoing, with advanced discussions with one interested party. Aker BioMarine has engaged Jefferies and Houlihan Lokey as investment banks to explore strategic alternatives for the Human Health Ingredients business, working toward a transaction in 2026.